In silico Screening of Plant Compounds to Inhibit MexB Efflux Protein for the Enhancement of Meropenem Resistance against Pseudomonas aeruginosa MDR Infections
Abstract
BACKGROUND
Pseudomonas aeruginosa is a common cause of healthcare-associated infections such as Pneumonia, Bloodstream, Urinary tract, and Surgical site infections this bacterium is also reported to cause infections in cancerous cells. It is one of the most considered opportunistic human pathogens, especially in immunocompromised patients, and one of the top five pathogens of nosocomial diseases worldwide. Some P. aeruginosa are becoming more resistant to even antibiotics of last resort, including beta-lactams, fluoroquinolones, tetracycline, chloramphenicol, macrolides, and aminoglycosides, and are described as multidrug-resistant. Multiple lines of evidence suggest that the chief mechanism for P. aeruginosa is resistance to antibiotics regulated by the efflux pumps. Antibiotic efflux pumps are membrane proteins that actively remove antibiotics from the bacterial cell, lowering on-target antibiotic concentrations to sub-toxic levels. The MexAB-OprM system is one of the largest multi-drug resistant clinically relevant efflux pumps with high expression levels in P. aeruginosa. Inhibition of these MDR efflux pumps can restore the activity of antimicrobial agents that are substrates for this protein. We performed molecular modelling studies in this study to discover novel Mex B efflux pump inhibitors. We evaluated the MIC of α-Bisabolol and Meropenem combination against Meropenem-resistant Pseudomonas Aeruginosa strains. This research opened up the possibility of using this…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.